Regulation of blood pressure by the type 1A angiotensin II receptor gene. 1995

M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
Department of Pathology, University of North Carolina, Chapel Hill 27599-7524, USA.

The renin-angiotensin system plays a critical role in sodium and fluid homeostasis. Genetic or acquired alterations in the expression of components of this system are strongly implicated in the pathogenesis of hypertension. To specifically examine the physiological and genetic functions of the type 1A receptor for angiotensin II, we have disrupted the mouse gene encoding this receptor in embryonic stem cells by gene targeting. Agtr1A(-/-) mice were born in expected numbers, and the histomorphology of their kidneys, heart, and vasculature was normal. AT1 receptor-specific angiotensin II binding was not detected in the kidneys of homozygous Agtr1A(-/-) mutant animals, and Agtr1A(+/-) heterozygotes exhibited a reduction in renal AT1 receptor-specific binding to approximately 50% of wild-type [Agtr1A(+/+)] levels. Pressor responses to infused angiotensin II were virtually absent in Agtr1A(-/-) mice and were qualitatively altered in Agtr1A(+/-) heterozygotes. Compared with wild-type controls, systolic blood pressure measured by tail cuff sphygmomanometer was reduced by 12 mmHg (1 mmHg = 133 Pa) in Agtr1A(+/-) mice and by 24 mmHg in Agtr1A(-/-) mice. Similar differences in blood pressure between the groups were seen when intraarterial pressures were measured by carotid cannulation. These studies demonstrate that type 1A angiotensin II receptor function is required for vascular and hemodynamic responses to angiotensin II and that altered expression of the Agtr1A gene has marked effects on blood pressures.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D010477 Perfusion Treatment process involving the injection of fluid into an organ or tissue. Perfusions
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006720 Homozygote An individual in which both alleles at a given locus are identical. Homozygotes
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
February 2000, Hypertension (Dallas, Tex. : 1979),
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
November 2002, Hypertension (Dallas, Tex. : 1979),
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
May 2002, Hypertension (Dallas, Tex. : 1979),
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
October 1994, Biochemical and biophysical research communications,
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
December 2017, American journal of physiology. Renal physiology,
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
June 1995, The Journal of steroid biochemistry and molecular biology,
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
February 1999, The Journal of pharmacology and experimental therapeutics,
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
November 1996, Hypertension (Dallas, Tex. : 1979),
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
November 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
M Ito, and M I Oliverio, and P J Mannon, and C F Best, and N Maeda, and O Smithies, and T M Coffman
January 2018, Current opinion in nephrology and hypertension,
Copied contents to your clipboard!